Staff Publications

Staff Publications

  • external user (warningwarning)
  • Log in as
  • language uk
  • About

    'Staff publications' is the digital repository of Wageningen University & Research

    'Staff publications' contains references to publications authored by Wageningen University staff from 1976 onward.

    Publications authored by the staff of the Research Institutes are available from 1995 onwards.

    Full text documents are added when available. The database is updated daily and currently holds about 240,000 items, of which 72,000 in open access.

    We have a manual that explains all the features 

Record number 370617
Title Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia
Author(s) Kolk, D.M. van der; Vellenga, E.; Scheffer, G.L.; Müller, M.R.; Bates, S.E.; Scheper, R.J.; Vries, E.G.E. de
Source Blood : journal of the American Society of Hematology 99 (2002)10. - ISSN 0006-4971 - p. 3763 - 3770.
DOI https://doi.org/10.1182/blood.V99.10.3763
Department(s) Chair Nutrition Metabolism and Genomics
VLAG
Publication type Refereed Article in a scientific journal
Publication year 2002
Keyword(s) bone-marrow transplantation - multidrug-resistance - p-glycoprotein - cell-lines - mitoxantrone-resistant - half-transporter - overexpression - gene - mrp1 - phenotype
Abstract Overexpression of the breast cancer resistance protein (BCRP) efflux pump in human cancer cell lines results in resistance to a variety of cytostatic agents. The aim of this study was to analyze BCRP protein expression and activity in acute myeloid leukemia (AML) samples and to determine whether it is up-regulated due to clonal selection at relapse/refractory disease. BCRP protein expression was measured flow cytometrically with the monoclonal antibodies BXP-34 and BXP-21 in 20 paired samples of de novo and relapsed/refractory AML. BXP-34/immunoglobulin G1 ratios were observed of 1.6 ± 0.5 (mean ± SD, range 0.8-2.7) and BXP-21/immunoglobulin G2a ratios of 4.9 ± 3.0 (range 1.1-14.5) in the patient samples versus 9.8 ± 6.8 and 6.5 ± 2.4, respectively, in the MCF-7 cell line. BCRP activity was determined flow cytometrically by measuring mitoxantrone accumulation in absence and presence of the inhibitor fumitremorgin C. Mitoxantrone accumulation, expressed as mean fluorescence intensity (MFI), varied between 44 and 761 MFI (227 ± 146 MFI) and correlated inversely with BCRP expression (r = 0.58, P <.001). Addition of fumitremorgin C showed a small increase in mitoxantrone accumulation (11 ± 29 MFI, n = 40) apart from the effect of PSC833 and MK-571. No consistent up-regulation of BCRP expression or activity was observed at relapse/refractory disease; some cases showed an increase and other cases a decrease at relapse. Relatively high BCRP expression correlated with immature immunophenotype, as determined by expression of the surface marker CD34 (r = 0.54, P = .001). In conclusion, this study shows that BCRP protein is expressed at low but variable levels in AML, especially in immature CD34+ cells. BCRP was not consistently up-regulated in relapsed/refractory AML
Comments
There are no comments yet. You can post the first one!
Post a comment
 
Please log in to use this service. Login as Wageningen University & Research user or guest user in upper right hand corner of this page.